What is Xarelto?
Xarelto is a direct factor Xa inhibitor drug that was originally approved in 2011 by the U.S. Food and Drug Administration as a preventative measure for people with atrial fibrillation. During the three years since the FDA first approved Xarelto for the open market, there have been over 1,800 adverse medical events linked to its use. These adverse events included:
- Bleeding ulcers
- Internal bleeding
- Lastly, severe or uncontrolled bleeding events
Dangers and Symptoms
Two main potentially life-threatening factors come with taking Xarelto. The first: the drug manufacturers may not properly shared the potentially serious health risks. Especially when they market it as a lifestyle friendly drug that doesn’t require regular follow-up doctor visits and blood monitoring. Secondly, once a severe internal bleeding episode begins, doctors cannot stop the bleeding. Due to the relaxed blood monitoring and office visits, the potential health risks of Xarelto are even higher among patients with poor kidney function.